Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of oxaliplatin + 5-fluorouracil before surgery for esophageal cancer
ISRCTN18146225Phase 2Completed
- Sponsor
- Churchill Hospital
- Start
- May 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and fluorouracil in esophageal cancer, sponsored by Churchill Hospital. Primary endpoints: DNA repair gene expression in tumor tissue and Clinical outcomes. Started May 2006; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ISRCTN18146225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18146225.